Abstract
Prophylactic efficiency and safety of anaferon (pediatric formulation) in children aging 1?month to 4 years, including sickly children, was proven. The use of the preparation in children reduced the incidence of acute respiratory infections, alleviated the course of the disease, and decreased the incidence of detection of viral antigens in nasal meatuses.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Antibodies / therapeutic use*
-
Antiviral Agents / therapeutic use*
-
Child, Preschool
-
Humans
-
Infant
-
Interferon Inducers / therapeutic use*
-
Interferon-gamma / metabolism
-
Respiratory Tract Infections / drug therapy*
-
Respiratory Tract Infections / prevention & control*
-
Respiratory Tract Infections / virology
-
Treatment Outcome
Substances
-
Antibodies
-
Antiviral Agents
-
Interferon Inducers
-
anaferon
-
Interferon-gamma